A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Episodic Cluster Headache Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache

Status Terminated

Clinical Trial Summary

This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult participants for the prevention of ECH.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02945046
Study type	Interventional
Source	Teva Branded Pharmaceutical Products R&D, Inc.
Contact
Status	Terminated
Phase	Phase 3
Start date	January 19, 2017
Completion date	May 13, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01341548` - Civamide Nasal Solution for Cluster Headache	Phase 3
Terminated	`NCT02209155` - R-Verapamil for the Prophylaxis of Episodic Cluster Headache	Phase 2
Unknown status	`NCT00399243` - Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache	Phase 4
Completed	`NCT02397473` - A Study Of Galcanezumab In Participants With Episodic Cluster Headache	Phase 3
Completed	`NCT02797951` - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache	Phase 3
Completed	`NCT00033839` - A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache	Phase 3
Completed	`NCT00069082` - Intranasal Civamide for Episodic Cluster Headache	Phase 3